JP2017522555A5 - - Google Patents

Download PDF

Info

Publication number
JP2017522555A5
JP2017522555A5 JP2016575349A JP2016575349A JP2017522555A5 JP 2017522555 A5 JP2017522555 A5 JP 2017522555A5 JP 2016575349 A JP2016575349 A JP 2016575349A JP 2016575349 A JP2016575349 A JP 2016575349A JP 2017522555 A5 JP2017522555 A5 JP 2017522555A5
Authority
JP
Japan
Prior art keywords
level
subject
protein
blood
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016575349A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017522555A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/038043 external-priority patent/WO2015200823A1/en
Publication of JP2017522555A publication Critical patent/JP2017522555A/ja
Publication of JP2017522555A5 publication Critical patent/JP2017522555A5/ja
Pending legal-status Critical Current

Links

JP2016575349A 2014-06-26 2015-06-26 多形膠芽腫(gbm)のためのマーカー及び治療指標 Pending JP2017522555A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462017748P 2014-06-26 2014-06-26
US62/017,748 2014-06-26
PCT/US2015/038043 WO2015200823A1 (en) 2014-06-26 2015-06-26 Markers and therapeutic indicators for glioblastoma multiforme (gbm)

Publications (2)

Publication Number Publication Date
JP2017522555A JP2017522555A (ja) 2017-08-10
JP2017522555A5 true JP2017522555A5 (enExample) 2018-08-02

Family

ID=54938849

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016575349A Pending JP2017522555A (ja) 2014-06-26 2015-06-26 多形膠芽腫(gbm)のためのマーカー及び治療指標

Country Status (6)

Country Link
US (1) US20170176439A1 (enExample)
EP (1) EP3161489A4 (enExample)
JP (1) JP2017522555A (enExample)
AU (1) AU2015279660A1 (enExample)
CA (1) CA2953459A1 (enExample)
WO (1) WO2015200823A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018177982A1 (en) 2017-03-30 2018-10-04 Administración General De La Comunidad Autónoma De Euskadi Sox1 as a prognostic and predictive biomarker in the treatment of central nervous system tumours
CN107653319B (zh) * 2017-10-27 2020-06-30 中南大学湘雅医院 胶质瘤诊断标志物circ8:61680968|61684188及应用
JP7211604B2 (ja) * 2017-12-05 2023-01-24 国立大学法人金沢大学 膠芽腫マーカー及びその使用
JP7029745B2 (ja) * 2017-12-05 2022-03-04 国立大学法人金沢大学 膠芽腫マーカー及びその使用
CN108956997A (zh) * 2017-12-29 2018-12-07 广西壮族自治区人民医院 Cd151蛋白表达量elisa检测方法及试剂盒
CN110211634B (zh) * 2018-02-05 2022-04-05 深圳华大基因科技服务有限公司 一种多组学数据联合分析的方法
AU2019361781A1 (en) * 2018-10-14 2021-06-03 Lantern Pharma Inc. Methods for the treatment of solid tumor cancers using illudins and biomarkers
CN114267447B (zh) * 2021-09-26 2025-05-06 吴安华 一种预测胶质母细胞瘤免疫微环境、预后及治疗敏感性的基因集及系统和方法
PL446389A1 (pl) * 2023-10-15 2025-04-22 Warszawski Uniwersytet Medyczny Nowe markery do diagnozowania glejaka wielopostaciowego oraz ich zastosowania

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2006122519A (ru) * 2003-12-24 2008-01-27 Сайос, Инк. (Us) Лечение злокачественных глиом ингибиторами тфр-бэта
CA2612021A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20090191202A1 (en) * 2005-09-29 2009-07-30 Jamieson Catriona Helen M Methods for manipulating phagocytosis mediated by CD47
CA2679943A1 (en) * 2007-03-02 2008-09-12 Board Of Regents, The University Of Texas System Multigene assay to predict outcome in an individual with glioblastoma
EP2377952A1 (en) * 2007-04-26 2011-10-19 Ludwig Institute For Cancer Research Methods for diagnosing and treating astrocytomas
US20120207753A1 (en) * 2009-08-21 2012-08-16 Centre Hospitalier Universitaire Vaudois Methods of using cd44 fusion proteins to treat cancer
US8404437B2 (en) * 2011-03-29 2013-03-26 Taipei Veterans General Hospital MicroRNA as a cancer progression predictor and its use for treating cancer

Similar Documents

Publication Publication Date Title
JP2017522555A5 (enExample)
Wolbink et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis
Elamm et al. Pathogenesis and diagnosis of myocarditis
Lopez-Vergès et al. Expansion of a unique CD57+ NKG2Chi natural killer cell subset during acute human cytomegalovirus infection
Valentini et al. An extensive analysis of disease-gene associations using network integration and fast kernel-based gene prioritization methods
McElhaney et al. Predictors of the antibody response to influenza vaccination in older adults with type 2 diabetes
Snir et al. Multifunctional T cell reactivity with native and glycosylated type II collagen in rheumatoid arthritis
Ghita et al. Global and cell type-specific immunological hallmarks of severe dengue progression identified via a systems immunology approach
JP2020510698A5 (enExample)
EA201590138A1 (ru) Оптимизация антител, которые связывают ген активации лимфоцитов 3 (lag-3), и их применение
JP2012524278A5 (enExample)
JP2010516678A5 (enExample)
JP2016513094A5 (enExample)
JP2017524130A5 (enExample)
JP2014521089A5 (enExample)
McDermott et al. Determining the breadth of the respiratory syncytial virus-specific T cell response
Jans et al. Siglec‐1 inhibits RSV‐induced interferon gamma production by adult T cells in contrast to newborn T cells
Claassen et al. Activation and inactivation of antiviral CD8 T cell responses during murine pneumovirus infection
JP2018504909A5 (enExample)
Lamers et al. Brain-specific HIV Nef identified in multiple patients with neurological disease
JP2016526167A5 (enExample)
WO2007011746A3 (en) Highly sensitive immunoassays and antibodies for detection of blood factor viii
WO2009133197A3 (en) Levels of april in serum and use in diagnostic methods
Lesgards et al. Do Long COVID and COVID Vaccine Side Effects Share Pathophysiological Picture and Biochemical Pathways?
Simões et al. Oral manifestations of lupus erythematosus–report of two cases